Guggenheim analyst Vamil Divan reiterated a Buy rating on Savara yesterday and set a price target of $11.00. The company’s shares closed yesterday at $5.08. Claim 55% Off TipRan ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 ...

New understanding about the pathophysiology of the condition, along with new clinical trial endpoints for approval, have ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

The EMBARK Awareness initiative is working to raise awareness of APOL-1 mediated kidney disease among high-risk populations ...

First quarter performance driven by strong year-over-year royalty revenue growth of 56%Reaffirms Previously Raised 2026 Full-Year Financial ...

ZYUS Life Sciences Corporation (the "Company") , a clinical-stage life sciences company focused on the development and ...

Nona Biosciences ("Nona" or the "Company"), a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the appointment of Dr. Josh Xiao ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the "Notes") ...

"I’m attending so that I can be seen and heard,” said AKF Ambassador Ashli Littleton, who lives in Clarksville, Tennessee and is attending the Kidney Action Summit for the first time. "We have to be ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 ...

FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year over ...